



# REVIEW RHINOPLASTY

# The Safety and Efficacy of Spreader Grafts and Autospreaders in Rhinoplasty: A Systematic Review and Meta-analysis

Cibele Madsen Buba<sup>1</sup> · Priyesh N. Patel<sup>2</sup> · Mikhail Saltychev<sup>3</sup> · Cherian K. Kandathil<sup>1</sup> · Sam P. Most<sup>1</sup>



Received: 15 November 2021/Accepted: 14 December 2021/Published online: 14 January 2022

© Springer Science+Business Media, LLC, part of Springer Nature and International Society of Aesthetic Plastic Surgery 2022

#### **Abstract**

Background The aim of this study was to systematically evaluate the evidence of surgical outcomes and complications of spreader grafts and autospreader flaps in the context of middle vault reconstruction after dorsal hump removal.

Material and Methods A systematic review was conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions. Inclusion and exclusion criteria were based on the population, intervention, comparison, and outcome (PICO) framework. Medline (via PubMed), EMBASE, Cinahl, Scopus, and Web of Science were searched for Clinical and observational studies published in peer-reviewed academic journals with abstracts available that reported rhinoplasty employing either spreader graft or autospreader flap techniques and were published prior to March, 2021.

Results Fifty-two of 1129 relevant studies were included in the qualitative analysis. Thirty-four studies (65.4%) were related to spreader graft (SG), 10 (21.1%) studies of autospreader flap (AF) alone and 8 (13.5%) studies involving both grafts. Meta-analysis was performed on 17

studies reporting change in NOSE scores, with pooled effect of -23.9 (95% CI, -26.7 to -21.1) points. High heterogeneity with  $I^2 = 99\%$ . Summary data showed no differences between groups, AF group versus no graft (p = 0.7578), AF versus SF group (p = 0.9948), and SG group versus no graft (p = 0.6608).

Conclusion Based on available data, change in NOSE scores after rhinoplasty was similar in procedures that used spreader graft only or autospreader flap only.

Level of Evidence III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266

 $\begin{tabular}{ll} \textbf{Keywords} & Systematic review \cdot Spreader grafts \cdot \\ Autospreader flaps \cdot Nasal obstruction \cdot Nasal cosmes is \cdot \\ Surgery outcome \\ \end{tabular}$ 

# Introduction

Rhinoplasty is one of the most frequently performed procedures in facial plastic surgery. The most common patient complaint is a "dorsal hump," followed by "too large" of a nose, "bulbous tip," and "nasal airway obstruction" [1]. Reduction in a dorsal hump alters the structure of the nose with resulting aesthetic and functional implications. The conservation of natural anatomical relationships to prevent functional sequelae of aesthetic nasal surgery has become an integral concept in rhinoplasty [2]. Since resection of the dorsal hump consists of the removal of an important portion of the osseocartilaginous dorsum, preservation, or reconstruction of the middle third of the nose is imperative to prevent midvault insufficiency, nasal valve dysfunction

- Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Stanford, CA 94305, USA
- Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA
- Department of Physical and Rehabilitation Medicine, Turku University Hospital and University of Turku, Turku, Finland



and/or an inverted-V deformity. Over the years, different techniques and grafts have been created so that this objective is achieved in dorsal hump reduction.

Since its description by Sheen, the spreader graft has become the gold standard for midvault reconstruction after hump resection [3]. A spreader graft is a rectangular strip of cartilage placed submucosally, along the superior border of the septum between the upper lateral cartilage and septum. It has been shown to preserve support of the nasal dorsum and function of the internal nasal valve [3]. It results in a wider dorsal roof, improved dorsal aesthetic lines and expands the internal valve angle, as it moves the lateral wall away from the septum [3]. In addition to being used for reduction rhinoplasty, spreader grafts have become an important technique to help straighten the deviated septum and nasal dorsum [4].

Release, preservation, and resuspension of the upper lateral cartilages to the dorsal septum were described by Fomon, though not in the context of dorsal hump reduction [5]. The more modern iteration, used in midvault reconstruction after dorsal hump reduction, was described by O'Neal and Berkowitz [6]. Spreader flaps, also known as autospreader flaps, are our primary method of midvault reconstruction after hump reduction.

Both the spreader graft and autospreader have been extensively studied and used throughout the years [2–4, 6, 9, 10, 14]. However, there is heterogeneity in the reported efficacy and outcome measures of these techniques and limited comparative data. Therefore, the aim of this study was to systematically compare the outcomes of spreader grafts and autospreader flaps in the context of midvault reconstruction after dorsal hump removal.

# **Materials and Methods**


A systematic review was conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions [7]. Inclusion and exclusion criteria were based on the population, intervention, comparison, and outcome (PICO) framework.

# **Population**

Adults (≥18 years) with nasal dorsal irregularities requiring nasal dorsal reconstruction with spreader graft or upper lateral cartilage turn-in flaps.

# Type of Studies

Clinical and observational studies published in peer-reviewed academic journals with abstracts available without restrictions on language or time of publication were



#### Intervention

Rhinoplasty employing either spreader graft or autospreader flap techniques. Dorsal hump reduction usually involves reducing the cartilaginous dorsal septum and trimming the vertical height of the upper lateral cartilages. The spreader graft is the standard method for stabilizing the middle vault. The upper lateral cartilage turn-in flap (autospreader or spreader flap) has later been introduced as a viable alternative to the spreader graft for middle nasal vault reconstruction.

# Comparison

Spreader graft versus autospreader flap technique

## **Outcome**

Difference between groups in the rates of complications and changes in nasal cosmesis and nasal obstruction severity levels before and after the surgery.

## **Data Sources and Searches**

Medline (via Pubmed), Embase, Cinahl, Central, Scopus, and Web of Science databases were searched in March 2021. To prevent losing any relevant studies, common search clauses were utilized. The search strategy for each database is as follows:

- Pubmed ((spreader [TIAB] OR autospreader[TIAB])
   AND (graft[TIAB] OR flap[TIAB])) OR ("turn in"
   [TIAB] AND cartilage) AND hasabstract[TW]
   EMBASE: (spreader:ab,ti OR autospreader:ab,ti) AND
   graft:ti,ab,kw AND 'human'/de AND 'article'/it AND
   'human'/de
- Cinahl ((TI spreader OR AB spreader OR TI autospreader OR AB autospreader) AND (TI graft OR AB graft OR TI flap OR AB flap)) OR ((TI "turn in" OR AB "in turn") AND (TI cartilage OR AB cartilage)) Limiters: Abstract Available Source Types: Academic Journals
- Central ((spreader OR autospreader) AND (graft OR flap)) OR ("turn in" AND cartilage) in Title Abstract Keyword in Trials



- Scopus ((TITLE-ABS-KEY ( spreader ) OR TITLE-ABS-KEY ( autospreader ) ) AND ( TITLE-ABS-KEY ( graft ) OR TITLE-ABS-KEY ( flap ) ) ) OR ( TITLE-ABS-KEY ( "turnin" ) AND TITLE-ABS-KEY ( cartilage ) ) AND ( LIMITTO ( EXACTKEY-WORD , "Rhinoplasty" ) ) AND ( LIMIT-TO ( EXACTKEYWORD , "Human" ) ) AND ( LIMIT TO ( DOCTYPE , "ar" ) )
- Web of science (TS= (((spreader OR autospreader) AND (graft OR flap) ) OR ("turn in" AND cartilage) ) OR TI= (((spreader OR autospreader) AND (graft OR flap) ) OR (("turn in"ANDcartilage) )))
   AND DOCUMENT TYPES: (Article) Indexes=SCI-EXPANDED Timespan=All years

# **Study Selection**

Search results were first screened based on titles and abstracts by two independent reviewers (C.M.B. and P.N.P.). The identified manuscripts were then screened on full texts according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline (Figure 1). Disagreements between the reviewers were resolved by consensus or by a third reviewer (C.K.K.).

Fig. 1 PRISMA Flow-diagram

# Assessment of Risk of Systematic Bias


The methodological quality of our systematic review was classified according to the Guidance for Assessing the Quality of Before–After (Pre–Post) Studies with No Control Group [60]. Twelve attributes were assessed: (1) study question or objective clearly stated; (2) study population and eligibility criteria; (3) study participants representative of clinical populations of interest; (4) all eligible participants enrolled; (5) sample size; (6) intervention clearly described; (7) outcome measures clearly described, valid, and reliable; (8) blinding of outcome assessors; (9) followup rate; (10) statistical analysis; (11) multiple outcome measures; and (12) group level interventions and individual-level outcome efforts. Quality of the included trials was estimated as poor, fair, or good.

#### **Data Extraction**

Relevant data were extracted from the records by 1 reviewer (C.M.B) using a predefined structured form and verified by a second reviewer (C.K.K).

## **Statistical Methods**

Seventeen studies reported NOSE scores with complete data. The NOSE score estimates reported by the original studies were pooled together depending on the use of





spreader grafts, autospreader or none, employing a random effects synthesis. The results were reported as weighted raw mean differences in the NOSE scores before and after the surgery. The results were accompanied by 95% confidence intervals (95% CIs). The heterogeneity was assumed being present if Q-statistics exceeded the degree of freedom (DF). The amount of heterogeneity related to true effect was assessed by using  $I^2$  statistics. The differences between treatment groups were assessed on the pooled summary data using ANOVA with Tukey HSD Post hoc Test setting a desired confidence level for post hoc confidence intervals at 95%. The results of ANOVA were reported as two-tailed p values considering p < 0.05statistically significant. All the analyses were carried out using the CMA software, version 3.3 available from www. meta-analysis.com and Stata/IC Statistical Software: Release 16. College Station (StataCorp LP, TX, USA).

# **Results**

The search yielded 1129 studies (Figure 1). After excluding duplicate records, reviews, case studies, conference proceedings, letters, and editorials, 441 records were screened by 2 independent reviewers based on titles and abstracts. The remaining 71 records were further assessed based on their full texts. Fifty-two studies [2, 4, 8–57] were included in the qualitative analysis. Of the 52 included studies, 16 were conducted in Turkey, 14 in the USA, 5 in Iran, 3 in Egypt, 3 in Italy, 3 in Canada, 2 in Germany, 1 in Brazil, 1 in South Korea, 1 in Portugal, 1 in Argentina, 1 in the Netherlands and 1 in Oman. Among them, 45 were observational in nature, with 13 retrospective studies (25.0%), 30 prospective studies (57.7%), 1 descriptive analytical study (1.9%), and 1 case series (1.9%). There were 6 randomized clinical trial (11.5%) and 1 non-randomized clinical trial (1.9%). There were 34 studies (65.4%) related to spreader graft (SG) alone [8–13, 16–23, 25, 27, 28, 30–34, 37, 40, 41, 43, 46–48, 50–52, 54, 55], 10 studies of autospreader flap (AF) alone (21.1%) [2, 24, 26, 29, 36, 39, 42, 49, 53, 56], and 8 studies involving (13.5%) both grafts [4, 14, 15, 35, 38, 44, 45, 57]. Sample size varied from 15 to 694, and the mean age varied from 13 to 73 years (Table 1). Among the identified 52 studies, 8 studies [8, 9, 18, 19, 25, 32, 47, 54] were found to have included patients aged less than 18 years of age in their cohort. Although this contradicts the adopted PICO framework for this review, it was decided to include these studies in the review as the patient cohorts in these studies included adult patients and due to the relevance of the study content to this review. Of the 52 studies, NOSE data were included in 19, but only 17 contained complete preoperative and postoperative data. Twenty-two

studies included patients who underwent revision surgery [8, 10–12, 18, 19, 22, 23, 27, 30–32, 34, 38, 41, 43, 46, 47, 52–55].

## Risk of Systematic Bias

Of the included 52 studies [2, 4, 8–57], methodologically, 25 (48.1%) were considered to be good [2, 4, 9, 13–15, 18, 20, 22–24, 30, 31, 33, 35, 37, 41, 42, 45–48, 50, 52, 57], 6 (11.5%) were considered poor [26, 32, 34, 38, 51, 53], and 21 (40.4%) were considered fair [8, 10–12, 16, 17, 19, 21, 25, 27–29, 36, 39, 40, 43, 44, 49, 54–56] (eTable 1).

## **Patient-Reported Outcome Measures**

Of the 52 studies, 19 reported NOSE [59] scores (Nasal Obstruction Symptom Evaluation Survey) [2, 9, 12, 15, 21–23, 29, 30, 33, 35, 41, 45, 47–50, 52, 56] (Table 2). However, only 17 [2, 9, 12, 15, 21–23, 29, 30, 33, 35, 45, 47, 49, 50, 52, 56] presented complete NOSE data preoperatively and postoperatively. Studies by Paul et al [41] and Talmadge et al [48] were excluded in the qualitative synthesis due to the lack of clarity of the data reported. The included 17 studies were divided into three groups (SG, AF and/or none) and the pooled estimates analyzed. Four of the 17 studies included the AF technique [2, 29, 49, 56], ten described the SG as the chosen technique [9, 12, 21–23, 30, 33, 47, 50, 52], and three reported both [15, 35, 45]. The overall preoperative and postoperative change in the NOSE score was -23.9 (95% CI, -26.7 to -21.1) points. The changes in the NOSE scores before and after the surgery were similar for all three groups, for AF they were -27.1 (95% CI, -36.2 to -18.0) points; for SG, they were -26.5 (95% CI, -30.4 to 22.6) points and for those where none of them were used, the scores were -19.9 (95% CI, -24.3 to -15.5) points (Table 3). The heterogeneity was substantial: overall Q = 7182, df 36,  $I_2 =$ 99%. The ANOVA for summary data (Tukey HSD Post hoc Test) showed no differences between groups, AF group versus no graft (p = 0.7578), AF versus SF group (p = 0.9948), and SG group versus no graft (p = 0.6608).

Six studies reported results using a VAS (Visual analog scale) [2, 4, 35, 37, 42, 56]. Three studies [2, 42, 56] reported scores for AF [2, 42, 56], one for SG [37] and two for both [4, 35] (Table 2). One study analyzed only functional aspects [37], three studies the aesthetic aspects [2, 35, 56] and two studies both aesthetic and functional aspects [4, 42]. The study by Hassanpour et al. [4] did not report preoperative and postoperative mean scores and standard deviation, only the percentage of satisfaction with appearance and function.



Table 1 Basic characteristics of included studies

Peac, Tignal   5 Autoopproacher   23	#	Study	и	Type of study (autospreaders, spreaders or both)	Mean age years	SD, years	Age range, years	Gender, % women	Available outcomes (functional, cosmetic, both)	Name of outcomes used
Graph et al. 18 discoperader         4 Autooptender         4 Autooptender         4 P-33         Fermale 13-70%, Male 18-73, M	-	Eren, Tugrul et al. [2]	15	Autospreader	32.2	6.3	*	Female 7 (47%), Male 8 (53%)	Functional	NOSE—Acoustic Rhinometry
Cybert Parts         2.5         Autospreader         *         Female 18-43, Male 23-458         Female 18-37, Male 23-458, Male 17-588, Male 17-588, Male 17-588, Male 17-588, Male 17-588, Male 18-34         Female 18-34, Male 23-55, Male 17-588, Male 17-588, Male 18-34         Female 18-34, Male 23-55, Male 18-34, Male 23-55, Male 18-34, Male 23-56, Male 23-56	7	Gorgulu et al. [24]	2	Autospreader	24	*	19–33	Female 45 (70%), Male 19 (30%)	Functional	Rhinomanometry
Hussein et al.   22 Autrospreader and Concert; 384, 45 per lander (17-6);   17-65   17-65   10 (45,459)   10 (45	8	Gruber, Park et al. [26]	25	Autospreader	*	*	Female 18-43, Male 23-55	Female 18 (72%), Male 7 (28%)	None	None
Stronke et al.   147 Autospreader   29.2   3.4     1.4   20.2     1.4   20.2     1.4   20.2     1.4   20.2     1.4   20.2     1.4   20.2     1.4   20.2     1.4   20.2     1.4   20.2   20.2     20.2   20.2   2	4	Hussein et al. [29]	22	Autospreader	24.68	*	18–35	Female 12 (54,54%), Male 10 (45,45%)	Functional	NOSE
Oxnea et al. [39]         180         Autrospreader         28.34         **         17-63         Fernale 14 (65%)           [39]         Saedi et al. [39]         6         Autrospreader         24.6         Autrospreader group: 25.96 SD         17-41         Fernale 14 (65%)           [42]         Try and Erden         54         Autrospreader         Autrospreader group: 25.96 SD         7.583. Let down group: 25.96 SD         8.583. Let down group: 25.96 SD         9.593. Let down group: 25.96 SD	S	Kucuke et al. [36]	147	Autospreader	29.2	*	17–65	*	None	None
Stead is ct al.         66         Autospreader         24.6         5.5         17-41         Fernale 46 (697%)           14-21         Tis and Erden         34         Autospreader group: 25.96 SD         4.0         Autospreader group: 37.36%         17.5-63         Fernale 46 (697.36%)           15-31         Wurm and         164         Autospreader         4.1         Fernale 133         Fernale 133           1 Yoo and Most Six         38         Autospreader and         4.1         4.1         Fernale 133         Fernale 133           1 Yoo and Most Six         38         Autospreader and         6.0         4.1         8.4         Fernale 133           1 Kroo and Most Six         38         Autospreader graft         8.6         1.46         1.8-64         Fernale 1456%).           1 Ksix         35 preader graft         32.1         4.6         1.46         1.8-64         Fernale 1464%).           1 Hassanpour         50         Autospreader graft         2.5         1.46         1.8-64         Fernale 1464%).           1 Hassanpour         50         Autospreader graft         2.5         1.46         1.8-64         Fernale 1464%).           1 Hassanpour         50         Autospreader graft         2.5         1.46	9	Ozmen et al. [39]	180	Autospreader	28.34	*	17–63	Female 114 (63%), Male 66 (37%)	None	None
Tag and Erden         54         Autospreader         Autospreader group: 26.35 SD         Autospreader group: 26.35 SD         Autospreader group: 26.32 SD         Autospread	7	Saedi et al. [42]	99	Autospreader	24.6	5.5	17–41	Female 46 (69,7%), Male 20 (30,3%)	Functional and Aesthetic	VAS—Acoustic Rhinometry
Vurm and Light Moore and Light Soverage of Expression and Moor 184 Autospreader and Sowder et al. 1856         14 Autospreader and Spreader flap: 38 A, Spreader flap: 38 A, Spreader graft and Soverage and Light Light Soverage and Light Light Soverage and Light Light Soverage and Light	6	Taş and Erden [49]	54	Autospreader	Autospreader group: 25.96 SD 7.583, Let down group: 26.52 SD 7.198	Autospreader group: 7.583, Let down group: 7.198	*	Female 31 (57,4%), Male 23 (42,6)	Functional	NOSE—SNOT-22
Yoo and Most 38         38 Autospreader and Sowder et al.         4         *         *           560         Soveder et al.         26 Autospreader and Spreader graft.         General: 38.4. Spreader flap: 38.         *         General: 18-64. Spreader flap: 38.         *           H451         Spreader graft         32.1         *         146         *         Female 14 (54%).           Barone et al.         264         Autospreader and Spreader graft         32.1         *         146         18-65         Female 154           Bigin et al.         60         Autospreader graft         28.6         1.46         18-50         Female 154           Hassanpour         50         Autospreader and Sayama         Autospreader graft	10	Wurm and Kovacevic [53]	261	Autospreader	*	*	17.5–63	Female 133 (81,1%), Male 31 (18,9%)	None	None
Sowder et al.         26         Autospreader and Spreader graft: 37.4         General: 1864, Spreader graft: 37.4         Female 14 (54%).           Barone et al.         264         Autospreader and state and sample and sam	11	Yoo and Most [56]	38	Autospreader	*	*	*	*	Functional and Aesthetic	NOSE—VAS
Barone et al.         264         Autospreader and Spreader graft         32.1         *         Female 154           [14]         Spreader graft         1.46         1.46         18-50         Female 33 (5%), Male 110 (41.7%)           Bilgin et al.         60         Autospreader graft         Autospreader graft         Autospreader graft         Autospreader graft         Autospreader graft         Autospreader graft         Pemale 37 (74%), Male 27 (45%)           Hassanpour         50         Autospreader and systam         *         Autospreader graft         Pemale 37 (74%), Male 27 (45%)           And Başaran         Spreader graft         \$         \$         Autospreader and systam         \$           Businesi and Başaran         36         Autospreader and systam         \$         \$         Autospreader and systam         \$           Buzen [44]         130         Autospreader graft         *         \$         *         *           Zeid et al. [57]         40         Autospreader graft         *         4         18-35         Female 14 (35%), Male 6 (17%)	∞	Sowder et al. [45]	26	Autospreader and Spreader graft	General: 38.4, Spreader flap: 38, Spreader graft: 37.4	*	General: 18–64, Spreader flap: 18–57, Spreader graft: 18–64	Female 14 (54%), Male 12 (46%)	Functional	NOSE
Bilgin et al.         60         Autospreader and Spreader graft         28.6         1.46         18-50         Female 33 (55%), Male 27 (45%)           Hassanpour         50         Autospreader and Autospreader and Başaran         Autospreader graft         Autospreader graft         *         Female 37 (74%), Male 13 (26%)           Manavbaşi         169         Autospreader graft         *         *         Female 112 (68%), Male 52 (32%)           Annavbaşi         189         Autospreader graft         *         *         Female 112 (68%), Male 52 (32%)           Kocak and Başaran         36         Autospreader graft         5.4         18-40         Female 30 (83%), Male 6 (17%)           Shrāaeei and Başari and Is3         130         Autospreader graft         *         *         *           Shrāaeei and Is4         180         Autospreader graft         *         *         *           Zeid et al. [57]         40         Autospreader graft         Autospreader graft         *         *           Zeid et al. [57]         40         Autospreader graft         Autospreader graft         *         *         *	12	Barone et al. [14]	264	Autospreader and Spreader graft	32.1	*	18–65	Female 154 (58,3%), Male 110 (41,7%)	Aesthetic	Face Q
Hassanpour         50         Autospreader and et al. [4]         Autospreader graft         Autospreader graft         Autospreader graft         Autospreader graft         Female 37 (74%), Amale 13 (26%)           Manavbaşi         169         Autospreader graft         *         *         Female 112 (68%), Amale 12 (68%)           Annavbaşi         169         Autospreader graft         *         *         Female 112 (68%), Amale 52 (32%)           Solzek and Başaran         36         Autospreader and Başaran         26.06         5.4         18-40         Female 30 (83%), Amale 6 (17%)           Shafaeei and Başaran         130         Autospreader and Basaran         *         *         *           Shafaeei and Basaran         130         Autospreader graft         *         *         *           Zeid et al. [57]         40         Autospreader graft         4         18-35         Female 14 (35%), Amale 26 (65%)	13	Bilgin et al. [15]	09	Autospreader and Spreader graft	28.6	1.46	18–50	Female 33 (55%), Male 27 (45%)	Functional	NOSE—Olfactory score
Manavbaşi         169         Autospreader and and Başaran         *         Female 112 (68%).           and Başaran         Spreader graft         *         *         Female 112 (68%).           Kocak and         36         Autospreader and Duzenli [35]         Spreader graft         *         *           Shafaeei and I [37]         Autospreader and Zare [44]         *         *         *           Zeid et al. [57]         40         Autospreader and Spreader graft         24         4         18-35         Female 14 (35%), Male 26 (65%)	4	Hassanpour et al. [4]	20	Autospreader and Spreader graft	Autospreader 24.64–Spreader graft 29.64	Autospreader: 5.08– Spreader graft: 9.02	*	Female 37 (74%), Male 13 (26%)	Functional and Aesthetic	Rhinomanometry—VAS
Kocak and         36         Autospreader and Duzenli [35]         5.4         18-40         Female 30 (83%), Male 6 (17%)           Duzenli [35]         Spreader graft         *         *         *           Shafaeei and Zare [44]         Spreader graft         4         18-35         Female 14 (35%), Male 26 (65%)	15	Manavbaşi and Başaran [38]	169	Autospreader and Spreader graft	*	*	*	Female 112 (68%), Male 52 (32%)	None	None
Shafaeei and 130 Autospreader and Zare [44]       *       *       *       *         Zare [44]       Spreader graft       *       Female 14 (35%), and so preader and spreader and spreader graft       24       4       18–35       Female 14 (35%), and so preader graft	16	Kocak and Duzenli [35]	36	Autospreader and Spreader graft	26.06	5.4	18–40	Female 30 (83%), Male 6 (17%)	Functional and Aesthetic	NOSE—VAS
Zeid et al. [57]         40         Autospreader and Autospreader and Spreader graft         24         4         18–35         Female 14 (35%), Male 26 (65%)	17	Shafaeei and Zare [44]	130	Autospreader and Spreader graft	*	*	*	*	None	None
	18	Zeid et al. [57]	40	Autospreader and Spreader graft	24	4	18–35	Female 14 (35%), Male 26 (65%)	Functional	Rhinomanometry



ntinued
le 1 cc
Table
<u> </u>
_

I a	Table 1 commued								
#	Study	и	Type of study (autospreaders, spreaders or both)	Mean age years	SD, years	Age range, years	Gender, % women	Available outcomes (functional, cosmetic, both)	Name of outcomes used
19	Al Abduwani and Singh [8]	179	Spreader graft	27.3	*	16–55	Female 43 (24,02%), Male 136 (75,97%)	None	None
20	Albergo et al. [9]	35	Spreader graft	31	*	13–66	Female 6 (17%), Male 29 (83%)	Functional	NOSE—Rhinomanometry
21	André et al. [10]	68	Spreader graft	38.6	*	21–65	Female 29 (32,58%), Male 60 (67,4%)	None	None
22	Arslan et al. [11]	25	Spreader graft	26.5	*	18–39	Female 18 (72%), Male 7 (28%)	None	None
23	Atespare and Boyaci [12]	115	Spreader graft	27.2	4.55	19–62	Female 50 (43,47%), Male 65 (56,52%)	Functional	NOSE
24	Atighechi et al. [12]	210	Spreader graft	25.54	5.68	18-45	Female 112 (53,3%), Male 98 (46,7%)	Functional	AlSarraf standardized questionnaire
25	Boccieri [16]	40	Spreader graft	32	*	19-48	Female 24 (%), Male 16 (%)	Functional	Rhinomanometry
26	Boccieri et al. [17]	09	Spreader graft	32	*	*	Female 25 (41,66%)–Male 35 (58,33%)	Functional	Rhinomanometry
27	Constantian and Clardy [18]	160	Spreader graft	Female: 34, Male: 34	*	Female 14–65, Male 17–72	Female 107 (67%), Male 53 (33%)	Functional	Rhinomanometry
28	Constantinides et al. [19]	27	Spreader graft	31	*	16–58	Female 17 (63%), Male 10 (37%)	Functional	Plethysmography
29	De Pochat et al. [20]	20	Spreader graft	31	9	20-40	Female 14 (70%), Male 6 (30%)	Functional	Acoustic Rhinometry
30	Erickson et al. [21]	17	Spreader graft	34.5	12.2	*	Female 16 (94%), Male 1 (6%)	Functional	NOSE—SNOT-22-Acoustic Rhinometry
31	Fuller et al. [22]	281	Spreader graft	36.3	15.5	*	Female 159 (56,6%), Male 122 (43,4%)	Functional	NOSE—PNIF
32	Fuller et al. [23]	154	Spreader graft	36.8	15.4	*	Female 82 (53,2%), Male 72 (46,8%)	Functional and Aesthetical	NOSE—FACE-Q
33	Grigoryants and Baroni [25]	32	Spreader graft	*	*	16–38	Female 24 (75%), Male 8 (25%)	None	None
34	Gürlek et al. [28]	20	Spreader graft	31	*	21-48	Female 8 (40%), Male 12 (60%)	None	None
35	Gurlek et al. [27]	15	Spreader graft	32	*	20-45	*	None	None
36	Ismail et al. [30]	79	Spreader graft	Female: 28, Male: 31	Female: 4, Male: 3	Female 18–42, Male 18–54	Female 23 (29%), Male 56 (71%)	Functional	NOSE



Tal	Table 1 continued	eq							
#	Study	u	Type of study (autospreaders, spreaders or both)	Mean age years	SD, years	Age range, years	Gender, % women	Available outcomes (functional, cosmetic, both)	Name of outcomes used
37	Jalali [31]	220	Spreader graft	Total: 28.3, Spreader graft group: 29.9	Total: 6.9 Spreader graft group: 5.8	*	Female 153 (70%), Male 67 (30%)	Functional	Rhinomanometry
38	Jang and Sinha [32]	33	Spreader graft	33	*	16–49	Female 6 (18%), Male 27 (82%)	None	None
39	Kahraman et al. [33]	50	Spreader graft	21	2.1	19–23	Female 0, Male 50 (100%)	Functional	NOSE—Acoustic Rhinometry
40	Khosh et al. [34]	53	Spreader graft	38	*	17–73	Female 29 (55%), Male 24 (45%)	None	None
4	Mamanov et al. [37]	30	Spreader graft	Group 1: 30.2, Group 2: 29.8	*	Group 1: 19–44, Group 2: 19–52	Female 13 (43%), Male 17 (57%)	Functional and Aesthetical	VAS—Acoustic Rhinometry
45	Ozturan [40]	92	Spreader graft	24	*	17–38	Female 26 (34%), Male 50 (66%)	None	None
43	Paul et al. [41]	38	Spreader graft	Closed surgery: 37.1, Open surgery: 36.9	Closed surgery: 12.5, Open surgery: 18.4	*	Female 20 (53%), Male 18 (47%)	Functional	NOSE—Acoustic Rhinometry
4	Samaha and Rassouli [43]	100	Spreader graft	31.2	*	*	Female 83 (83%), Male 17 (13%)	None	None
45	Stacey et al. [46]	34	Spreader graft	Group 1 (Butterfly): 47, Group 2 (Spreader): 29	*	*	Female 23 (67,6%) Male 11 (32,4%)	Functional and Aesthetical	Nasal airway obstruction questionnaire
46	Standlee and Hohman [47]	109	Spreader graft	33	*	16–68	Female 21 (19%), Male 88 (81%)	Functional	NOSE
47	Talmadge et al. [48]	50	Spreader graft	Open approach: 40, Endonasal: 42	*	*	Open: Female 17 (34%), Male 33 (66%). Endonasal: Female (35%), Male (65%).	Functional	NOSE
48	Ulusoy et al. [50]	89	Spreader graft	With spreader: 26.8, Without spreader: 29.7	With spreader: 6.7, Without spreader: 7.3	With spreader: 19–42), Without spreader: 17–48	Female 39 (57,3%), Male 29 (42,7%)	Functional	NOSE
49	Wagner and Schraven [51]	100	Spreader graft	*	*	*	*	None	None
50	Weitzman et al. [52]	694	Spreader graft	SSG: 34.8, ESG: 42.7	SSG: 14.8, ESG: 16.4	*	Female 333 (47,9%), Male 361 (52,1%)	Functional and Aesthetical	NOSE—FACE-Q
51	Xavier et al. [54]	72	Spreader graft	31.74	10.74	16–58	Female 34 (47,22%), Male 38 (52,78%)	Functional	PNIF
52	Yoo and Jen [55]	41	Spreader graft	32	*	19–56	Female 22 (53,7%), Male 19 (46,3%)	None	None

\*No data available



Table 2 Nasal obstruction symptom evaluation score and visual analog scale score

ļ											
#	Study	Type (auto spreaders=1, spreaders=2)	Outcome	Follow-up interval	Groups	Mean preop score	SD	Range	Mean postop score	SD	Range
1	Eren et al. [2]	1	NOSE	12.6 months		99	13	20–80	7.7	10	0–35
2	Hussein et al. [29]	_	NOSE	6-12 months	Group 1(aesthetic only)	5.9		0-10	1.36		0-5
					Group 2(Functional+aesthetic only)	67.27		50–85	18.63		05-25
8	Tas and Erden [49]	1	NOSE	6 months	ler		5.019		3.93	3.812	
4	Yoo and Most [56]	1	NOSE	150 days (range: 30-619)	Group 2(Letdown) 13	15.04	3.2200	10.5	4.89 12	4.309	
5	Albergo et al. [9]	2	NOSE	14 months (12–16)	74.5		55–90	23.5		09-0	
9	Atespare and Boyaci [12]	2	NOSE	12 months		3.14	0.35		0.81	0.75	
7	Erickson et al. [21]	2	NOSE	Early—8.1 +/-1.6 weeks	14	3.3	10-20	Early: 5.9	2.9	02-10	
				Intermediate—17.2 +/-4.2 Weeks				Intermediate: 7.7	4.5	0-15	
∞	Fuller et al. [23]	2	NOSE	5.8 (4.1) months, range: 2–12 months)			20.9		21.8	20.3	
6	Fuller et al. [22]	2	NOSE	7.3 (5.4) months Range: 2–24 months	Functional + Cosmetic: 61.8	62.5 22	20.2	20.9	26.3 2.4	23.2	
10	Ismail et al. [30]	2	NOSE	0-1 month, 1-3 months, 6-3 years	8.69	8.7	58–89	20.65	8.4	17–24	
11	Kahraman et al. [33]	2	NOSE	1 month	Group 1(septoplasty):	16.8	1.3		2.4	0.5	
					Group2 (Septoplasty with spreader graft) :	15.4	2.4		2.4	1.8	
					Group 3 (septorhinoplasty ):	15.2	1.3		3.6	1.1	
					Group 4 (Septorhinoplasty with spreader graft):	16.4	2.3		8.8	2.8	
12	Standlee and Hohman [47]	2	NOSE	Follow-up interval 1 (Mean): 52 days; Follow-up interval 2 (Mean): 115 days; Follow-up interval 3 (Mean): 191 days	69	18		23	20		
13	Paul et al. [41]	2	NOSE	12 months		reported as median (Total scores not x5)	2.1–2.85			0.75–1.1	



1   Thingle ct at   2   2   2   2   2   2   2   2   2												
Tableache et al.   2   NOSE   6-12 months   Depart   Evolutional Computer	#	Study	Type (auto spreaders=1, spreaders=2, both =3)	Outcome	Follow-up interval	Groups	Mean preop score		Range	Mean postop score		Range
Second   1, 50   1,	14	Talmadge et al. [48]	2	NOSE	0–12 months	Open	70			17		
University   2   Comparing the content of the con						Endonasal	99			16		
Compact Open Squired in the compact of the compac	15		2	NOSE	6 months	Group1( Open Septorhinoplasty with b/l spreader grafts)	61.2		14–75	24		15–59
Weigham et al. [35]         2         50.5         10.4         10.5						Group2( Open Septorhinoplasty without spreader grafts)	63.1		16–78	27		15–67
Bigin et al.   15    3   10   10   10   10   10   11   1   10	16		2	NOSE	0-6, 6-12 months	Spreader graft	63.9	22.5		20.4	19.5	
Biggin et al. [15]   3   NOSE   Not specified   Group 1: M spreader grafts:   115   0.517   1.6   1.		,				Extended Spreader graft	63.9	24.6		27.6	26.3	
Crowder ct at   45   5   5   5   5   5   5   5   5	17		3	NOSE	Not specified	Group 1: b/l spreader grafts:	11.6		)6–17	1.6		7-0
Second and Duzenti 3   Oceanit   Coronit   C						Group 2: b/l spreader flaps:	9.5	Ū	11-17	2.5		0-10
Secretary Duzenit 3   NoSE   Anomhs   NoSE   Anomhs   NoSE   NO						Group3: No flaps or grafts:	11.5		)5–18	1.4		9-0
Sympatic and Duzonii 3   NOSE   3 months   Rectingular graft   22   22   22   22   22   22   22						Overall:	10.87		)1–18	1.83		9-0
Spreader flap   256   267   9.5   7.4     Spreader flap   268   18.4   10.5   1.5     Spreader flap   268   18.4   10.5   1.5     Spreader flap   268   18.4   10.5   1.5     Spreader flap   268   1.5   1.5   1.5     Spreader Gail flap   2.5   2.5   1.5     Spreader Gail flap   2.5   2.5   2.5     Manamov et al.   2.5   2.5   2.5     Spreader Gail flap   2.5   2	18		3	NOSE	3 months	Rectangular graft	22.2	20.2		8.2	5.7	
Storder ct al. [45] 3 NOSE 1.3.6 months Spreader flap 268 184 61 165 165 174 185 185 185 185 185 185 185 185 185 185		,				Triangular graft	35.6	26.7		9.5	7.2	
Sowder et al. [45] 3 NOSE 1, 3, 6 months Spreader Graft Flap P. 153 6 17-491 4 18.5 16.4 16.4 18.5 19.6 19.6 19.6 19.6 19.6 19.6 19.6 19.6						Spreader flap	26.8	18.4		10.5	7.4	
Spreader Graft   194   164	19		3	NOSE	1, 3, 6 months	Spreader Flap	81.9		72.4-91.4	18.5		5.4-31.5
Spreader Flap   Spreader Graft   Sprea						Spreader Graft	75.4		53.7-87.1	16.9	16.4	7.0-26.8
Spreader Flap   Spreader Graft   Sprea										Change In NOSE		
Spreader Graft						Spreader Flap				63.5	23.5	49.3–77.7
Eren, Tugul et al. 1         VAS         126 months         12         01-20         88         9           Yoo and Most [56]         1         VAS         150 days (ranger. 30-619)         12         16         0.95         1.2         9         9           Mannanov et al. [37]         2         6 months         Group I: Open Septorhinoplasty (SRP)         5.53         2.83         5.53         1.2         8         2.83						Spreader Graft				58.5		41.7–75.3
Yoo and Most [56] 1         VAS (months)         Group I: Open Septorhinoplasty (SRP)         1.6         0.95         1.2           Mamanov et al. [37]         2         VAS (months)         Group I: Open Septorhinoplasty (SRP)         5.53         2.83         5.53           R VAS         After Decongestion:         4.73         2.52         5.27           R VAS         Before decongestion:         4.27         2.49         4.27           After Decongestion:         After Decongestion:         3.87         2.29         4.27           R VAS         Before decongestion:         4.4         2.59         2.67           R VAS         After Decongestion:         3.87         2.13         2.2           R VAS         After Decongestion:         4.4         2.59         2.67           R VAS         After Decongestion:         3.87         2.13         2.4	-	Eren, Tugrul et al.	1	VAS	12.6 months		32.5		01–20	88	6	70–100
Mamanov et al.         2         VAS         6 months         Group 1: Open Septorhinoplasty (SRP)         5.53         2.83         5.53           137]         L VAS         After Decongestion:         4.73         2.52         5.27           R VAS         Before decongestion:         4.27         2.49         4.27           After Decongestion:         3.87         2.29         4.27           Group 2: Open SRP+ Spreader grafts         4.4         2.59         2.67           After Decongestion:         3.87         2.13         2.2           R VAS         Before decongestion:         3.87         2.13         2.2           R VAS         Before decongestion:         5.27         3.28         2.4	7	Yoo and Most [56]	_	VAS	150 days (range: 30–619)	1.2	1.6		.95	1.2		
L VAS       Before decongestion:       5.53       2.83       5.53         R VAS       Before decongestion:       4.77       2.49       4.27         After Decongestion:       After Decongestion:       3.87       2.29       4.27         L VAS       Before decongestion:       4.4       2.59       2.67         R VAS       Before decongestion:       3.87       2.13       2.2         Before decongestion:       5.27       3.28       2.4	3	Mamanov et al. [37]	2	VAS	6 months	Group 1: Open Septorhinoplasty (SRP)						
After Decongestion: 4.73 2.52 5.27  Before decongestion: 4.27 2.49 4.27  After Decongestion: 3.87 2.29 4.27  Group 2: Open SRP+ Spreader grafts  Before decongestion: 3.87 2.13 2.2  Before decongestion: 5.27 3.28 2.4  After Decongestion: 5.27 3.28 2.4				L VAS		Before decongestion:	5.53	2.83		5.53	2.83	
Before decongestion:       4.27       2.49       4.27         After Decongestion:       3.87       2.29       4.27         Group 2: Open SRP+ Spreader grafts       4.4       2.59       2.67         Before decongestion:       3.87       2.13       2.2         Before decongestion:       5.27       3.28       2.4         After Decongestion:       4.8       2.91       2.4						After Decongestion:	4.73	2.52		5.27	2.55	
Before decongestion:       4.27       2.49       4.27         After Decongestion:       3.87       2.29       4.27         Group 2: Open SRP+ Spreader grafts       4.4       2.59       2.67         Before decongestion:       3.87       2.13       2.2         Before decongestion:       5.27       3.28       2.4         After Decongestion:       4.8       2.91       2.4				R VAS		,						
After Decongestion: 3.87 2.29 4.27  Group 2: Open SRP+ Spreader grafts  Before decongestion: 3.87 2.13 2.2  After Decongestion: 5.27 3.28 2.4  After Decongestion: 5.27 3.28 2.4						Before decongestion:	4.27	2.49		4.27	2.49	
Group 2: Open SRP+ Spreader grafts       4.4       2.59       2.67         Before decongestion:       3.87       2.13       2.2         Before decongestion:       5.27       3.28       2.4         After Decongestion:       4.8       2.91       2.4						After Decongestion:	3.87	2.29		4.27	2.49	
Before decongestion:         4.4         2.59         2.67           After Decongestion:         3.87         2.13         2.2           Before decongestion:         5.27         3.28         2.4           After Decongestion:         4.8         2.91         2						Group 2: Open SRP+ Spreader grafts						
After Decongestion: 3.87 2.13 2.2  Before decongestion: 5.27 3.28 2.4  After Decongestion: 4.8 2.91 2				L VAS		Before decongestion:	4.4	2.59		2.67	6.0	
Before decongestion: 5.27 3.28 2.4 After Deconastion: 4.8 2.01 2						After Decongestion:	3.87	2.13		2.2	89.0	
5.28 2.4				R VAS		-	i C	ć		-	-	
· · · · · · · · · · · · · · · · · · ·						Before decongestion:	5.2/	3.28		4.7	1.18	



Ta	Table 2 continued										
#	Study	Type (auto spreaders=1, spreaders=2, both =3) Outcome	Outcome	Follow-up interval Groups		Mean preop score	SD 1	Range	Mean preop score SD Range Mean postop score SD Range	SD	Range
4	Hassanpour et al. [4]	3	VAS	1 month		Not reported			Not reported		
2	Kocak and Duzenli [35] 3	3	VAS	3months	Rectangular graft 4.07	4.07	1.8		8.8	_	
					Triangular graft	3.3	1.5		8.7	6.0	
					Spreader flap	4	1.9		8.8	0.7	
9	Saedi et al. [42]	12 months	VAS (Satisfaction) 12 months	12 months	Spreader Flap	4.43	2.49		8.38	1.6	
					Control	3.83	1.72		89.8	0.95	
			VAS (Obstruction) Spreader Flap	Spreader Flap	5.57	2.51		2.56	0.52		
					Control	6.17	3.28		3.2	1.47	



Among fifteen studies (28.9%) reporting acoustic rhinomanometry, two were AF related studies [24, 42], eleven were SG studies [2, 9, 16–18, 20, 21, 31, 33, 37, 41] and two studies related with both AF and SG [4, 57] (Table 4). Eight studies (15.4%) reported both preoperative and postoperative outcomes, as well as standard deviations [16, 18, 21, 33, 37, 41, 42, 57]. Six of eight studies about SG reporting complete data were [16, 18, 21, 33, 37, 41], one was about AF [42], and one studied both SG and AF [57]. Seven other studies (13.5%) [2, 4, 9, 17, 20, 24, 31] reported objective outcomes; however, they did not register complete data to compare the changes between preoperative and postoperative results. Due to this reason, a qualitative synthesis was not carried out.

## Risks of Complications or Revision Surgery

Of the 52 studies included, 18 studies (34.6%) reported proportion of revision surgery and details of complications [8–11, 16–18, 20, 26, 30, 31, 34, 36, 38, 39, 41, 43, 53]. Complications were reported in 13 of 34 SG studies (38.2%); in 4 of 11 AF studies (36.4%) and in 1 of 7 combined SG and AF studies (14.3%) (eTable 2). Revision rates were reported in 5 of 34 SG studies (14.7%), in 2 of 11 AF studies (18.2%) and 1 of 7 for combined studies (14.2%) (eTable 2). Bleeding ranged from 0 to 4.47%, infection from 0 to 5.62%, aesthetic complications excluding dorsal irregularities from 0 to 11.73%, other functional complications from 0 to 15.0%, and revision surgery from 0 to 6.12%. Of the 34 SG studies (pooled: n =3326), there were 8 infections (0.24%), 9 bleeding events (0.27%), no dorsal irregularities, 29 other cosmetic complications (0.87%), and 46 other functional complications (1.38%). Of the 5 studies reporting revision rates (n = 367)[8, 9, 16, 17, 34], there were 14 revisional procedures (3.81%). In the 11 AF studies (pooled: n = 801), there were 16 other cosmetic complications (2.00%), 10 other functional complications (1.25%), no infections, no dorsal irregularities, and no bleeding events. One study (n = 147)[38] reported revision surgery for 9 cases (6.12%). Of the 7 studies involving both SG and AF (pooled n = 749), there was 1 other cosmetic complication. Manavbaşi and Başaran [38] reported that a patient-reported problems resulting from excessive dorsal width, excessive swelling in the supratip area and demanded removal of the grafts in the second postoperative week. There were no infections, no bleeding events, no other functional complications, and no dorsal irregularities. Only one study (pooled n = 169) [38] described a revision procedure in 1 patient (0.60%).



Table 3 Change in nasal obstruction symptom evaluation score across the analyzed studies.

	Study	WMD	95%	6 CI	N			
	Eren 2014	-57.30	-62.68	-51.92	15	-	-	
	Hussein 2015a	-4.54	-5.73	-3.35	11			
S	Hussein 2015b	-48.64	-52.78	-44.50	11		-	
Autospreaders	Tas 2021a	-9.03	-10.57	-7.49	27			
ea	Yoo2011a	-2.50	-8.07	3.07	21			-
spi	Yoo2011b	-40.10	-48.09	-32.11	17		-	
1 약	Bilgin 2021b	-7.00	-8.40	-5.60	20			
₹	Kocak 2018c		-24.88	-7.72	12		-	<b></b>
	Sowder 2017a	-63.40	-72.92	-53.88	13	_	<del></del>	
	Group total	-27.13	-36.21	-18.04	147			<b>&gt;</b>
	Tas 2021b	-8.15	-9.81	-6.49	27			
	Kahraman 2016a	-14.40	-15.07	-13.73	10			
None	Kahraman 2016c	-11.60	-12.27	-10.93	10			
9	Standlee 2017a	-46.00	-51.66	-40.34	35			
-	Ulusoy 2016b	-36.10	-39.34	-32.86	33			
	Bilgin 2021c	-10.10	-11.26	-8.94	20			
	Group total	-19.90	-24.27	- 15.53	135		•	
	Albergo 2020	-51.00	- 54.98	-47.02	35		-	
	Atespare 2016a	-12.75	-13.27	-12.23	115			-
	Atespare 2016b	-11.65	-12.21	-11.09	115			-
	Atespare 2016c	-11.50	-12.05	-10.95	115			-
	Atespare 2016d	-11.80	-12.45	-11.15	115			•
	Atespare 2016e	-13.55	-14.09	-13.01	115			•
	Erickson 2016a	-8.10	-9.56	-6.64	14			-
	Erickson 2016b	-6.30	-8.36	-4.24	12			-
fts	Fuller, Levesque 2019a	<b>- 41.00</b>	-44.83	<b>–</b> 37.17	89		+	
g	Fuller, Levesque 2019b	-36.20	-40.96	-31.44	65		<del>  = -</del>	
Spreader grafts	Fuller, Gadkaree 2019c	-40.90	-43.31	-38.49	281		+	
ad	Ismail 2018	<b>–</b> 49.15	-50.69	-47.61	79		-	
ore	Kahraman 2016b	-13.00		-11.79	10			•
S	Kahraman 2016d		-13.04	10.16	10			•
	Standlee 2017b		-49.89	-42.11	74			
	Ulusoy 2016a	-37.20	-39.69	-34.71	35		-	
	Weitzman 2020a		-45.06	-41.94	568		-	
	Weitzman 2020b	-36.30	-40.28	-32.32	126		-	
	Bilgin 2021a		-10.97	-9.03	20			•
	Kocak 2018a		-23.11	-4.89	14			<b></b>
	Kocak 2018b		-40.42	<b>–</b> 11.78	10		-	<del></del>
	Sowder 2017b		-67.29	-49.71	13	_	-	
	Group total		-30.39		2030		•	,
	Total	-23.89	-26.67	-21.12	2312		•	<b>)</b>
						-80.00	-40.00	0.00

WMD weighted mean difference, CI confidence interval, N number of patients



 Table 4 Results of acoustic rhinomanometry

 # Study
 Type (Auto spreaders=1,

#	Study	Type (Auto spreaders=1, spreaders=2, Both =3)	Follow-up interval (SD), range	Groups		Mean preop score	SD 1	Range/ Percentage	Mean postop SD score	Range/ Percentage
-	Gorgulu et al. [24]	1	18 months (12-24)	Group 1: Inspiratory NARs		0.257		0.224-0.276	0.144	0.132-0.163
				Group 2: Expiratory NARs		0.194		0.162-0.216	0.138	0.126-0.159
2	Saedi et al. [42]	1	12 months	Spreader flap group	Left I-notch area	0.71	0.19		0.7	0.17
					Right I-notch area	0.75	0.2		0.73	0.26
					Left C-notch area	0.76	0.48		0.69	0.17
					Right C-notch	1.13	1.07		2.3	1.99
					Left MCA	0.71	0.2		1.2	0.46
					Right MCA	0.76	0.21		0.73	0.26
					Left volume	6.9	11.7		11.26	16.28
					Right volume	4.6	2.24		8.07	7.33
				Control group	Left I-notch area	0.83	0.53		9.0	0.15
					Right I-notch area	0.84	0.81		0.55	0.19
					Left C-notch area	0.92	0.64		9.0	0.15
					Right C-notch	1.34	1.45		0.79	0.28
					Left MCA	89.0	0.19		1.17	0.48
					Right MCA	0.67	0.19		0.55	0.2
					Left volume	7.28	8.41		5.67	4.66
					Right volume	7	11.9		4	96.0
$\epsilon$	Hassanpour et al. [4]	_		Autospreader flap	Nasal airway resistance	0.14			0.24	
					Flow rate	412.14			276.62	
4	Zeid et al. [57]			Autospreader flap	Right nasal cavity's resistance	0.82	0.23		0.37 0.04	
					Left nasal cavity's resistance	0.74	0.14		0.35 0.03	
_	Albergo et al. [9]	2	14 months (12-16)			5.9	Ŭ	0-46	6.0	0-2
2	Boccieri [16]	2	20 months (14-26)		Quiet inspiration	308	34		523 64	
					Forced inspiration	1.034	107		1.759 157	
$\epsilon$	Boccieri et al. [17]	2	17 months (12-24)	NO VALUES/TABLES						
4	Constantian and Clardy [18]	2	8.4 months (1–43)	Internal + external valves + septum	Quiet inspiration	93	22		459 87	
					Forced inspiration	624	123		1222 162	
				Internal + external valves	Quiet inspiration	234	9		884 139	
					Forced inspiration	1080	359		~	
				Internal valve + septum	Quiet inspiration	250	51		556 83	



Freeding indication   Freeding indication   266   37   178   184   297   184   297   184   297   184   297   184   297   184   297   184   297   184   297   184   297   184   297   184   297	#   #	Study	Type (Auto spreaders=1, spreaders=2. Both =3)	Follow-up interval (SD), range	Groups			Mean	SD	Range/ Percentage		Mean postop score	SD	Range/ Percentage
Part			, , , , , , , , , , , , , , , , , , , ,					score		0		1 1		0
Proceeding which with the process and the pr						Forced inspiration		983	178			1864	297	
Freed injoining					Internal valves (all)	Quiet inspiration		266	37			529	69	
Parali graftic   Para						Forced inspiration		934	113			1765	163	
Proceedings   Proceding   Pr					Dorsal graft reconstruction	Quiet inspiration		236	59			477	107	
Proceding time   Proc						Forced inspiration		1001	193			1528	252	
Expendity of the principal continuous cont					Spreader graft reconstruction	Quiet inspiration		284	42			560	91	
External valve   Exte						Forced inspiration		891	141			1904	210	
Forced impointion   1860   1					External valve + septum	Quiet inspiration		165	42			477	94	
Separation   Sep						Forced inspiration		504	130			1760	371	
Percent   Percent inspiration   Faced inspir					External valves	Quiet inspiration		238	92			809	291	
Procedual Control Line   Procedual Control Line Line   Procedual Control Line Line   Procedual Control Line Line Line Line Line Line Line Line						Forced inspiration		1114	246			1437	357	
Proceed inspiration   Proceed in a processor   Proceed in a processor   Proceed in a processor   Proceed in a processor   Processor					Septum	Quiet inspiration		442	101			478	106	
Prochat   2						Forced inspiration		1069	189			1579	188	
Ecce of al 2   2   12 6 months   Mean minimal cross   156 cm²		De Pochat et al. [20]	2	5–18 months	NO VALUES/ TABLES									
Etickson 2 Marcas ectional A Sil weeks (1.6)		Fren et al. [2]	2	12.6 months		Mean minimal cross- sectional area		1.56 cm <sup>2</sup>				2.16 cm <sup>2</sup>		
1.77 weeks (4.2)   1.97 weeks (2.9)   Spreader grafts   1.97 will will will will will will will wil		Erickson et al. [21]	2	8.1 weeks (1.6)		INV cross-sectional area		0.519	0.28	0.02-1.10	Early postoperative	0.614	0.28	0.19-1.32
Jabil [31]         2         Co.9 weeks (2.9)         Spreader grafts         Co.9 meeks (2.9)         Spreader grafts         August         0.247 Ped m/s         0.100-0.250         0.017 Pa/ml/s         0.110-0.130         0.110-0.120         0.110-0.120         0.110-0.120				17.7 weeks (4.2)							Intermediate postoperative	0.552	0.23	0.17-1.01
Flating sutures   Flating sutures   Haring   H		alali [31]	2	20.9 weeks (2.9)	Spreader grafts			0.247 Pa/ ml/s	0.110-0.250		0.027 Pa/ml/ s	0.110-0.130		
Kathraman         2         The months         Group 1         Deviated side (cm²)         MCA 2 (cm²)         0.34 (cm²)         0.28 (cm²)         0.56           et al. [33]         ACA 2 (cm²)         0.31 (cm²)         0.35         0.5         0.5           Vol 1         1.69 (cm²)         0.79 (cm³)         1.83         4.06         1.83           Vol 2         ACA 2 (cm²)         0.46 (cm²)         0.5         0.5         0.46           MCA 2 (cm²)         (cm²)         (cm²)         0.21         0.48         0.48           Vol 1         1.88 (cm²)         0.39         0.39         0.33         0.39					Flaring sutures			0.247 Pa/ ml/s	0.120-0.930		0.017 Pa/ml/s	0.690-0.790		
MCA 2 (cm²) (cm²)         0.31         0.35         0.5           Vol 1 (cm³) (cm³)         1.69         0.79         1.83           Vol 2 (cm³)         3.85         2.5         4.06           MCA 1 (cm²) (cm²)         0.21         0.5           MCA 2 (cm²) (cm²)         0.27         0.48           Vol 1 (cm³) (cm³)         1.88         0.39         2.03		Kahraman et al. [33]	2	12 months	Group 1	Deviated side	$\begin{array}{c} \text{MCA 1} \\ \text{(cm}^2) \end{array}$	0.34	0.28			0.56	0.24	
Vol 1       1.69       0.79       1.83         (cm³)       3.85       2.5       4.06         (cm³)       MCA 1       0.46       0.21       0.5         MCA 2       0.49       0.27       0.48         (cm²)       Vol 1       1.88       0.39       2.03							MCA 2 $(cm2)$	0.31	0.35			0.5	0.43	
Vol 2       3.85       2.5       4.06         (cm³)       0.46       0.21       0.5         MCA 2       0.49       0.27       0.48         (cm²)       Vol 1       1.88       0.39       2.03         (cm³)       (cm³)       2.03							Vol 1 (cm <sup>3</sup> )	1.69	0.79			1.83	0.74	
MCA 1 0.46 0.21 0.5 (cm²) MCA 2 0.49 0.27 0.48 (cm²) Vol 1 1.88 0.39 2.03							$\begin{array}{c} \text{Vol 2} \\ \text{(cm}^3) \end{array}$	3.85	2.5			4.06	2.54	
0.49     0.27     0.48       1.88     0.39     2.03						Non deviated side	MCA 1 $(cm2)$	0.46	0.21			0.5	0.26	
1.88 0.39 2.03							MCA 2 $(cm2)$	0.49	0.27			0.48	0.29	
							Vol 1 (cm³)	1.88	0.39			2.03	0.56	



g
continu
COL
4
e
9
g a
_

Table 4 Continued										
# Study Type (Auto spreaders=1, spreaders=2, Both Follow-up interval (SD), =3)	Follow-up interval (SD), range	Groups			Mean preop score	SD	Range/ Percentage	Mean postop score	SD R	Range/ Percentage
				Vol 2 (cm <sup>3</sup> )	3.93	1.78		4.16	2.12	
		Group 2	Deviated side	$\begin{array}{c} \text{MCA 1} \\ \text{(cm}^2) \end{array}$	0.33	0.16		0.54	0.29	
				MCA 2 $(cm2)$	0.29	0.22		0.49	0.29	
				$Vol 1 (cm^3)$	1.56	99.0		1.74	0.58	
				Vol 2 (cm <sup>3</sup> )	3.74	1.19		3.78	2.21	
			Non deviated side	MCA 1 $(cm2)$	0.39	0.11		0.41	0.08	
				MCA 2 $(cm2)$	0.42	0.2		0.43	0.25	
				Vol 1 $(cm^3)$	1.65	9.0		1.79	0.31	
				Vol 2 (cm <sup>3</sup> )	4.05	0.73		4.17	2.14	
		Group 3	Deviated side	$\begin{array}{c} \text{MCA 1} \\ \text{(cm}^2) \end{array}$	0.29	0.2		0.49	0.1	
				MCA 2 $(cm2)$	0.32	0.3		0.55	0.1	
				Vol 1 (cm <sup>3</sup> )	1.73	0.65		1.75	0.4	
				Vol 2 (cm <sup>3</sup> )	4.13	1.38		4.29	98.0	
			Non deviated side	$\begin{array}{c} \text{MCA 1} \\ \text{(cm}^2) \end{array}$	0.41	0.18		0.46	0.26	
				MCA 2 $(cm2)$	0.39	0.13		0.42	0.34	
				$Vol 1 (cm^3)$	1.82	0.39		1.91	0.55	
				$Vol 2 (cm^3)$	4.31	0.93		4.35	2	
		Group 4	Deviated side	$\begin{array}{c} \text{MCA 1} \\ \text{(cm}^2) \end{array}$	0.32	0.21		0.51	0.26	
				MCA 2 $(cm2)$	0.3	90.00		0.53	0.3	
				Vol 1 (cm <sup>3</sup> )	1.47	0.58		1.59	0.61	
				$Vol 2 (cm^3)$	3.88	1.77		4.09	1.46	
			Non deviated side	$MCA 1$ $(cm^2)$	0.35	0.15		0.39	0.12	
				$MCA 2$ $(cm^2)$	0.37	0.15		0.4	0.08	
				$Vol 1 (cm^3)$	1.64	0.45		1.82	0.51	
				$Vol 2 (cm^3)$	3.96	1.91		4.18	1.24	
		Control	Control Deviated side	$MCA 1$ $(cm^2)$	0.5	0.07				
				$MCA 2$ $(cm^2)$	0.59	0.07				
				$Vol 1 (cm^3)$	1.94	0.2				
				Vol 2 (cm <sup>3</sup> )	4.17	0.62				



Range/ Percentage 0.23 0.49 0.78 2.45 0.26 0.28 0.46 0.22 1.38 9. 0.22 0.43 0.24 0.21 0.24 0.02 0.0 SD Mean postop score 265.04 0.37 0.47 0.55 1.84 99.0 0.38 0.47 1.67 0.43 0.49 1.66 1.01 0.35 3.22 0.51 2.05 0.53 4.4 Range/ Percentage 0.11 0.09 0.23 2.46 0.23 0.62 0.48 0.23 1.46 0.25 0.43 0.24 SD 0.21 1.05 0.5 0.24 0.3 0.2 Mean preop score 483.08 0.87 3.16 4.35 0.52 0.63 0.42 2.04 0.47 1.81 0.63 0.26 2.01 4.22 0.47 1.65 0.51 0.48 1.63 0.54 0.64 69.0 0.5 R MCA2  $(cm^2)$ L MCA1 (cm²) R MCA1 (cm<sup>2</sup>) L MCA1 (cm²) L VOL1 (cm³) L VOL2 R VOL1 (cm³) L VOL1 (cm³) L VOL2 (cm<sup>3</sup>) R MCA1 (cm<sup>2</sup>) R VOL1 (cm<sup>3</sup>) Vol 2 (cm³)  $\begin{array}{c} \text{Vol 1} \\ \text{(cm}^3) \end{array}$  $(cm^3)$ MCA2 (cm<sup>2</sup>) $(cm^2)$  $\begin{array}{c} MCA2 \\ (cm^2) \end{array}$ Nasal airway resistance Overall average cross-Before decongestion Right nasal cavity's resistance After decongestion Left nasal cavity's resistance Non deviated side sectional area Flow rate Group 1: Spreader graft Spreader graft Groups Follow-up interval (SD), range 6 months 6 months 1 month 4 weeks Type (Auto spreaders=1, spreaders=2, Both =3) 7 Paul et al. [41] 2 Table 4 continued Zeid et al. [57] Hassanpour et al. [4] et al. [37] Mamanov Study 10 Ξ 12 13



When comparing SG versus AF, the relative risk for infections was 4.10 (95% CI, 0.24–70.93); for bleeding was 4.58 (95% CI, 0.27–78.61); for nasal dorsal irregularities was 0.24 (95% CI, 0.0048–12.14); for other aesthetic complications was 0.4365 (95% CI, 0.24–0.80); for other functional complications was 1.11 (95% CI, 0.56–2.19); and for revision surgery was 0.37 (95% CI, 0.16–0.86).

# **Discussion**

This study systematically evaluated outcomes and complications of SG and AF in 52 studies. Less than half of the studies included in this review, 25 of 52 (48.1%) demonstrated good methodology according to the Guidance for Assessing the Quality of Before–After (Pre–Post) Studies with no control group [58]. Meta-analysis included only 17 studies that reported both preoperative and postoperative NOSE scores [59]. Based on 95% CI, the change in NOSE for SG: -26.5 (95% CI, -30.4 to 22.6) is insignificant statistically, whereas the ones for AF: -27.1 (95% CI, -36.2 to -18.0) points, and for no grafts: -19.9 (95% CI, -24.3 to -15.5) especially in that closest to a zero effect level, AF =18.0 and 'none at all'=15.5 are both less than 19.4 the reported MCID for NOSE. There was high heterogeneity ( $I^2 = 99\%$ ) between the three groups).

Of the 52 studies included, rates of revision surgery and complications were described in 18 studies: 13 related to the SG technique [8–11, 16–18, 20, 30, 31, 34, 41, 43], 4 related to the AF technique [26, 36, 39, 53] and 1 related to using both grafts [38]. Revision surgery rates were reported in 5 of 34 studies for SG, in 1 of 11 studies for AF and 1 of 7 for studies that used both grafts. Other functional complications (1.38%) were the most prevalent among the spreader graft group, followed by other cosmetic complications (0.87%). Among the autospreader flap group, other cosmetic complications (2.00%) were more numerous when compared to other functional ones (1.25%) (eTable 2). Other complications, such as bleeding and infections, were not found to be significantly different between the 2 groups. Overall, these complication rates were very low, all occurring at rates less than 2%. More prevalent was revision surgery, which was slightly higher for the patients that were submitted to procedures that used both SG and AF (14.2%) or SG only (14.7%), when compared to those undergoing the AF technique (9.1%).

Five studies, four evaluating the spreader graft technique [21, 33, 37, 41] and one evaluating the autospreader flap technique [42] reported increase in the minimal cross-sectional area postoperatively. Two studies using spreader grafts showed that nasal airflow during quite inspiration improved postoperatively [16, 18]. One study [57] comparing the nasal air resistance in patients that were

submitted to rhinoplasty with spreader grafts or autospreader flaps reported decrease in air resistance in both groups postoperatively. Despite the improvements in these objective outcomes, it is difficult to compare and to affirm what graft is more efficient, since the data were collected by analyzing different groups or parameters.

As various modifications have been suggested for the autospreader flaps, it is unclear if certain aspects like scoring the autospreader flaps have any impact on outcomes.

# Limitations

We understand the complexity of this chosen topic of middle vault management. Not all spreader grafts or flaps are the same. Moreover, each surgeon also has their respective modification of these grafts. Due to such differences, there exists an inherent problem obtaining a standardized result in the management of the middle vault. One of the main limitations of the study was the lack of consistent methodology among the included studies in this review, coupled with the heterogeneity of reported outcomes, were the main limitations of this study. Over half of the included studies were assessed to be of low quality. While 52 studies were included for the qualitative analysis, most of them did not include complete outcome data or the lack of standardized reporting of patient outcomes in these studies, a major shortcoming, makes it difficult to effectively compare both methods.

### Conclusion

Of the 52 studies reviewed, less than half were considered to have a good methodology and only 17 were included for the quantitative analysis. Discrepancies in the functional and/or aesthetic outcome measures made comparisons difficult. To increase the reliability and level of evidence, surgical outcomes measures should be standardized, and improved study methodology is required. We recommend a highly validated and extensively translated PROM like the standardized cosmesis and health nasal outcomes survey (SCHNOS) questionnaire to be accepted as a global standard in assessing rhinoplasty patients [60–72]. As stated by the available data, change in NOSE scores after rhinoplasty were similar in procedures that used spreader graft only or autospreader flap only. Complications did not differ significantly between groups. Considering that the results of this systematic review and meta-analysis demonstrated that there were no significant differences between the two techniques, based on surgeon preference, it may be



beneficial to use autospreader flaps since it limits the need for cartilage harvest.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00266-021-02735-0.

Funding None to declare

#### **Declarations**

Conflict of interest The authors have no conflicts of interest to disclose.

**Human and Animal Rights** This article does not contain any studies with human participants or animals performed by any of the authors.

**Informed Consent** For this type of study, informed consent is not required.

## References

- Chauhan N, Alexander AJ, Sepehr A, Adamson PA (2011) Patient complaints with primary versus revision rhinoplasty: analysis and practice implications. Aesthet Surg J 31(7):775–780. https://doi.org/10.1177/1090820X11417427
- Eren SB, Tugrul S, Ozucer B et al (2014) (2014) Autospreading spring flap technique for reconstruction of the middle vault. Aesthet Plast Surg 38:322–328. https://doi.org/10.1007/s00266-014-0292-8
- Sheen JH (1984) Spreader graft: a method of reconstructing the roof of the middle nasal vault following rhinoplasty. Plast Reconstr Surg 73:230–239
- Hassanpour SE, Heidari A, Moosavizadeh SM, Tarahomi MR, Goljanian A, Tavakoli S (2016) Comparison of aesthetic and functional outcomes of spreader graft and autospreader flap in rhinoplasty. World J Plast Surg 5(2):133–138
- Fomon S, Caron A (1950) Collapsed ala. Acta Otolaryngol 51:465–484
- Oneal RM, Berkowitz RL (1998) Upper lateral cartilage spreader flaps in rhinoplasty. Aesthetic Surg J 18(5):370–371. https://doi. org/10.1016/S1090-820X(98)70095-0
- Higgins JPT (2011) Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. London, UK. http://handbook.cochrane.org
- Al Abduwani J, Singh A (2015) Impact of osteotomies and structural grafts in the management of severe twisted or deviated nasal deformity: a critical analysis of 179 patients with open rhinoplasty. Am J Otolaryngol 36(2):210–216. https://doi.org/10. 1016/j.amjoto.2014.10.035
- Albergo L, Desio E, Revelli VE, Acosta MB (2020) Spreader graft for severe deviation of nasal septum with obstruction of the internal nasal valve: clinical and functional results. Fac Plast Surg 36(5):635–642. https://doi.org/10.1055/s-0040-1713794
- André RF, Paun SH, Vuyk HD (2004) Endonasal spreader graft placement as treatment for internal nasal valve insufficiency: no need to divide the upper lateral cartilages from the septum. Arch Fac Plast Surg 6(1):36–40. https://doi.org/10.1001/archfaci.6.1.36
- Arslan E, Majka C, Beden V (2007) Combined use of triple cartilage grafts in secondary rhinoplasty. J Plast Reconstr Aesthet Surg 60(2):171–179. https://doi.org/10.1016/j.bjps.2006.04.014

- Atespare A, Boyaci Z (2016) The use of spreader grafts in revision septoplasty. J Craniofac Surg 27(7):1656–1660. https:// doi.org/10.1097/SCS.000000000002898
- Atighechi S, Sarafraz Z, Baradaranfar M, Dadgarnia M, Zand V, Meybodian M, Mandegari M, Shirkhoda S, Vaziribozorg S (2018) The effect of spreader graft and mattress suture technique on rhinoplasty in patients with nasal hump smaller than 3 mm. J Craniofac Surg 29:2110–2113. https://doi.org/10.1097/SCS. 00000000000005078
- 14. Barone M, Cogliandro A, Salzillo R, Colapietra A, Alessandri Bonetti M, Morelli Coppola M, List E, Ciarrocchi S, Tenna S, Persichetti P (2019) Role of spreader flaps in rhinoplasty: analysis of patients undergoing correction for severe septal deviation with long-term follow-up. Aesthet Plast Surg 43(4):1006–1013. https://doi.org/10.1007/s00266-019-01343-3
- Bilgin E, Kaya Celik E, Baklaci D, Say MA, Dalgic M (2021) Evaluation of the use of different spreader techniques in primary open septorinoplasty in terms of nasal and olfactory functions.
   J Craniofac Surg. https://doi.org/10.1097/SCS. 00000000000007485
- Boccieri A (2005) Mini spreader grafts: a new technique associated with reshaping of the nasal tip. Plast Reconstr Surg 116(5):1525–1534. https://doi.org/10.1097/01.prs.0000182787. 99210.10
- Boccieri A, Macro C, Pascali M (2005) The use of spreader grafts in primary rhinoplasty. Ann Plast Surg 55(2):127–131. https://doi.org/10.1097/01.sap.0000168707.71596.f6
- Constantian MB, Clardy RB (1996) The relative importance of septal and nasal valvular surgery in correcting airway obstruction in primary and secondary rhinoplasty. Plast Reconstr Surg 98(1):38–58. https://doi.org/10.1097/00006534-199607000-00007
- Constantinides MS, Adamson PA, Cole P (1996) The long-term effects of open cosmetic septorhinoplasty on nasal air flow. Arch Otolaryngol Head Neck Surg 122(1):41–45. https://doi.org/10. 1001/archotol.1996.01890130035005
- de Pochat VD, Alonso N, Mendes RR, Cunha MS, Menezes JV (2012) Nasal patency after open rhinoplasty with spreader grafts.
   J Plast Reconstr Aesthet Surg 65(6):732–738. https://doi.org/10.1016/j.bjps.2011.11.059
- Fuller JC, Gadkaree SK, Levesque PA, Lindsay RW (2019) Peak nasal inspiratory flow is a useful measure of nasal airflow in functional septorhinoplasty. Laryngoscope 129(3):594–601. https://doi.org/10.1002/lary.27566
- Fuller JC, Levesque PA, Lindsay RW (2019) Analysis of patient-perceived nasal appearance evaluations following functional septorhinoplasty with spreader graft placement. JAMA Fac Plast Surg 21(4):305–311. https://doi.org/10.1001/jamafacial.2018. 2118
- 24. Görgülü T, Özer CM, Kargi E (2015) The accordion suture technique: a modified rhinoplasty spreader flap. J Craniomaxillofac Surg 43(6):796–802. https://doi.org/10.1016/j.jcms.2015.03.036
- Grigoryants V, Baroni A (2013) The use of short spreader grafts in rhinoplasty for patients with thick nasal skin. Aesthet Plast Surg 37(3):516–520. https://doi.org/10.1007/s00266-013-0103-7
- Gruber RP, Park E, Newman J, Berkowitz L, Oneal R (2007) The spreader flap in primary rhinoplasty. Plast Reconstr Surg



- 119(6):1903–1910. https://doi.org/10.1097/01.prs.0000259198.
- Gürlek A, Ersoz-Ozturk A, Celik M, Firat C, Aslan S, Aydogan H (2006) Correction of the crooked nose using custom-made high-density porous polyethylene extended spreader grafts. Aesthet Plast Surg 30(2):141–149. https://doi.org/10.1007/s00266-005-0152-7
- Gürlek A, Celik M, Fariz A, Ersöz-Oztürk A, Eren AT, Tenekeci G (2006) The use of high-density porous polyethylene as a custom-made nasal spreader graft. Aesthet Plast Surg 30(1):34–41. https://doi.org/10.1007/s00266-005-0119-8
- Hussein WK, Elwany S, Montaser M (2015) Modified autospreader flap for nasal valve support: utilizing the spring effect of the upper lateral cartilage. Eur Arch Otorhinolaryngol 272(2):497–504. https://doi.org/10.1007/s00405-014-3309-7
- Ismail A, Hussein W, Elwany S (2018) Combining spreader grafts with suture suspension for management of narrow internal nasal valve angles. Turk Arch Otorhinolaryngol 56(1):25–29. https://doi.org/10.5152/tao.2018.2996
- Jalali MM (2015) Comparison of effects of spreader grafts and flaring sutures on nasal airway resistance in rhinoplasty. Eur Arch Otorhinolaryngol 272(9):2299–2303. https://doi.org/10.1007/ s00405-014-3327-5
- Jang YJ, Sinha V (2007) Spreader graft in septo-rhinoplasty. Indian J Otolaryngol Head Neck Surg 59(2):100–102. https://doi. org/10.1007/s12070-007-0031-4
- Kahraman E, Cil Y, Incesulu A (2016) The effect of nasal obstruction after different nasal surgeries using acoustic rhinometry and nasal obstruction symptom evaluation scale. World J Plast Surg 5(3):236–243
- 34. Khosh MM, Jen A, Honrado C (2004) Pearlman SJ (2004) Nasal valve reconstruction: experience in 53 consecutive patients. Arch Fac Plast Surg 6(3):167–171. https://doi.org/10.1001/archfaci.6.3.
- Kocak OF, Düzenli U (2018) Assessment of vertical triangular spreader graft technique for reconstruction of middle vault and internal nasal valve angle. J Craniofac Surg 29(8):2096–2100. https://doi.org/10.1097/SCS.0000000000004939
- Küçüker I, Özmen S, Kaya B, Ak B, Demir A (2014) Are grafts necessary in rhinoplasty? Cartilage flaps with cartilage-saving rhinoplasty concept. Aesthet Plast Surg 38(2):275–281. https:// doi.org/10.1007/s00266-013-0258-2
- Mamanov M, Batioglu-Karaaltin A, Inci E, Erdur ZB (2017)
   Effect of spreader graft on nasal functions in septorhinoplasty surgery. J Craniofac Surg 28(7):e618–e621. https://doi.org/10. 1097/SCS.000000000000003613
- Manavbaşı YI, Başaran I (2011) The role of upper lateral cartilage in dorsal reconstruction after hump excision: section 1.
   Spreader flap modification with asymmetric mattress suture and extension of the spreading effect by cartilage graft. Aesthet Plast Surg 35(4):487–493. https://doi.org/10.1007/s00266-010-9641-4
- Ozmen S, Ayhan S, Findikcioglu K, Kandal S, Atabay K (2008)
   Upper lateral cartilage fold-in flap: a combined spreader and/or splay graft effect without cartilage grafts. Ann Plast Surg 61(5):527–532. https://doi.org/10.1097/SAP.0b013e31816dd359
- Ozturan O (2000) Techniques for the improvement of the internal nasal valve in functional-cosmetic nasal surgery. Acta Otolaryngol 120(2):312–315. https://doi.org/10.1080/ 000164800750001152
- 41. Paul MA, Kamali P, Chen AD, Ibrahim AM, Wu W, Becherer BE, Medin C, Lin SJ (2018) Assessment of functional rhinoplasty with spreader grafting using acoustic rhinomanometry and validated outcome measurements. Plast Reconstr Surg Glob Open 6(3):e1615. https://doi.org/10.1097/GOX.00000000000001615
- 42. Saedi B, Amaly A, Gharavis V, Yekta BG, Most SP (2014) Spreader flaps do not change early functional outcomes in

- reduction rhinoplasty: a randomized control trial. Am J Rhinol Allergy 28(1):70–74. https://doi.org/10.2500/ajra.2014.28.3991
- Samaha M, Rassouli A (2015) Spreader graft placement in endonasal rhinoplasty: technique and a review of 100 cases. Plast Surg (Oakv) 23(4):252–254. https://doi.org/10.4172/plasticsurgery.1000944
- Shafaeei Y, Zare NJ (2019) A comparison of the aesthetics outcomes and respiratory side effects of the use of spreader flap and spreader graft techniques in open rhinoplasty. J Craniofac Surg 30(8):2546–2548. https://doi.org/10.1097/SCS.00000000000005744
- 45. Sowder JC, Thomas AJ, Gonzalez CD, Limaye NS, Ward PD (2017) Use of spreader flaps without dorsal hump reduction and the effect on nasal function. JAMA Fac Plast Surg 19(4):287–292. https://doi.org/10.1001/jamafacial.2016.2057
- Stacey DH, Cook TA, Marcus BC (2009) Correction of internal nasal valve stenosis: a single surgeon comparison of butterfly versus traditional spreader grafts. Ann Plast Surg 63(3):280–284. https://doi.org/10.1097/SAP.0b013e31818d45fb
- Standlee AG, Hohman MH (2017) Evaluating the effect of spreader grafting on nasal obstruction using the NOSE scale. Ann Otol Rhinol Laryngol 126(3):219–223. https://doi.org/10.1177/ 0003489416685320
- Talmadge J, High R, Heckman WW (2018) Comparative outcomes in functional rhinoplasty with open versus endonasal spreader graft placement. Ann Plast Surg 80(5):468–471. https://doi.org/10.1097/SAP.000000000001434
- Taş BM, Erden B (2021) Evaluation of the effect of conventional rhinoplasty with autospreader flap and let-down technique on nasal functions. Fac Plast Surg 37(03):302–305. https://doi.org/ 10.1055/s-0041-1722955
- Ulusoy S, Dinç ME, Dalğıç A, Dizdar D, Avınçsal MÖ, Külekçi M (2016) Effects of spreader grafts on olfactory function in septorhinoplasty. Aesthet Plast Surg 40(1):106–113. https://doi.org/10.1007/s00266-015-0597-2
- Wagner W, Schraven SP (2011) Spreader grafts in der Septorhinoplastik1 [Spreader grafts in septorhinoplasty]. Laryngorhinootologie 90(5):264–274. https://doi.org/10.1055/s-0030-1270471
- Weitzman RE, Gadkaree SK, Justicz NS, Lindsay RW (2021) Patient-perceived nasal appearance after septorhinoplasty with spreader versus extended spreader graft. Laryngoscope 131(4):765–772. https://doi.org/10.1002/lary.28974
- 53. Wurm J, Kovacevic M (2012) Flaring spreader flaps" und "upper lateral advancement". Modifizierte Techniken zur Rekonstruktion der inneren Nasenklappe [Flaring spreader flaps and upper lateral advancement. Modified techniques in the reconstruction of the internal nasal valve]. HNO 60(7):597–604. https://doi.org/10.1007/s00106-011-2427-4
- Xavier R, Azeredo-Lopes S, Papoila A (2015) Spreader grafts: functional or just aesthetical? Rhinology 53(4):332–339. https://doi.org/10.4193/Rhin13.069
- Yoo DB, Jen A (2012) Endonasal placement of spreader grafts: experience in 41 consecutive patients. Arch Fac Plast Surg 14(5):318–322. https://doi.org/10.1001/archfaci.2012.173
- 56. Yoo S, Most SP (2011) Nasal airway preservation using the autospreader technique: analysis of outcomes using a diseasespecific quality-of-life instrument. Arch Fac Plast Surg 13(4):231–233
- 57. Zeid NG, Mohamed AS, ElSayed EM, Azooz KO, Aleryan MM, Abd Elmottaleb Sabaa M (2020) Objective comparison between spreader grafts and flaps for mid-nasal vault reconstruction: a randomized controlled trial. Plast Surg (Oakv) 28(3):137–141. https://doi.org/10.1177/2292550319880919
- National Heart, Lung, and Blood Institute. Study quality assessment tools. <a href="https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools">https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools</a>



- Stewart MG, Witsell DL, Smith TL, Weaver EM, Yueh B, Hannley MT (2004) Development and validation of the nasal obstruction symptom evaluation (NOSE) scale. Otolaryngol-Head Neck Surg 130(2):157–163. https://doi.org/10.1016/2Fj. otohns.2003.09.016
- Moubayed SP, Ioannidis JPA, Saltychev M, Most SP (2018) The 10-item standardized Cosmesis and health nasal outcomes survey (SCHNOS) for functional and cosmetic rhinoplasty. JAMA Fac Plast Surg 20:37–42
- Kandathil CK, Saltychev M, Abdelwahab M, Spataro EA, Moubayed SP, Most SP (2019) Minimal clinically important difference of the standardized cosmesis and health nasal outcomes survey. Aesthet Surg J 39(8):837–840
- 62. Saltychev M, Kandathil CK, Abdelwahab M, Spataro EA, Moubayed SP, Most SP (2018) Psychometric properties of the standardized cosmesis and health nasal outcomes survey: item response theory analysis. JAMA Fac Plast Surg 20(6):519–521
- 63. Saltychev M, Kandathil CK, Abdelwahab M, Spataro EA, Moubayed SP, Most SP (2019) Confirmatory factor analysis of the standardized cosmesis and health nasal outcomes survey. Plast Reconstr Surg 143(2):454e–456e
- 64. Kandathil CK, Saltychev M, Patel PN, Most SP (2020) Natural history of the standardized cosmesis and health nasal outcomes survey after rhinoplasty. Laryngoscope 131(1):E116–E123
- Spataro EA, Kandathil CK, Saltychev M, Olds CE, Most SP (2020) Correlation of the standardized cosmesis and health nasal outcomes survey with psychiatric screening tools. Aesthet Surg J 40(12):1373–1380
- Gode S, Ozturk A, Sahin M, Berber V, Apaydin F (2019) Turkish validation of the standardized cosmesis and health nasal outcomes survey. Fac Plast Surg 35(4):397–399

- Abdelwahab M, Saltychev M, Elkholy N, Elsisi H, Moubayed S, Most S (2019) Arabic validation of the standardized cosmesis and health nasal outcome survey for arabic-speaking rhinoplasty patients. Plast Reconstr Surg 143(3):673e–675e. https://doi.org/ 10.1097/PRS.00000000000005357
- 68. Rahavi-Ezabadi S, Most SP, Saltychev M, Sazgar AA, Moubayed SP, Saedi B (2018) Validation of the Persian language version of the standardized cosmesis and health nasal outcomes survey (SCHNOS). JAMA Fac Plast Surg 20(6):521–523
- Choi WR, Kim SA, Kim SH, Jang YJ (2020) Validation of the Korean version of the standardized cosmesis and health nasal outcomes survey. Korean J Otorhinolaryngol-Head Neck Surg 63(4):163
- Tunes RS, Patrocinio LG, Saltychev M, Moubayed SP, Sam P (2020) Validation of the portuguese language version of the standardized cosmesis and health nasal outcomes survey most. Fac Plast Surg Aesthet Med 22(2):114–116
- Perez-Garcia IC, Peñaranda A, Cobo R, Hernandez AV, Moubayed SP, Most SP (2019) Spanish translation, cultural adaptation, and validation of the standardized cosmesis and health nasal outcomes survey questionnaire. Plast Reconstr Surg Glob: Open 7(3):e2153. https://doi.org/10.1097/GOX.00000000000002153
- Atallah M, Milad D, Benamer Y et al (2019) Translation, cultural adaptation and validation of the SCHNOS in French. J of Otolaryngol: Head Neck Surg 48:17

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

